Compare Stocks → See this before next week's Fed meeting (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ADXSNASDAQ:ASLNNASDAQ:FWPNASDAQ:MNPRNASDAQ:ONCS Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADXSAyala Pharmaceuticals$0.55+1.9%$0.70$0.50▼$1.95$5.91M1.6220,556 shs203 shsASLNASLAN Pharmaceuticals$0.45-3.4%$0.60$0.39▼$4.69$7.42M1.45991,319 shs171,536 shsFWPForward Pharma A/S$1.95$2.17$1.50▼$6.48$13.83M1.387,484 shsN/AMNPRMonopar Therapeutics$0.62-5.5%$0.75$0.27▼$1.75$10.84M1.194.28 million shs27,671 shsONCSOncoSec Medical$0.52$0.18▼$20.46$1.26M1.992.22 million shs52.49 million shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADXSAyala Pharmaceuticals0.00%-16.34%-14.29%-10.00%-56.45%ASLNASLAN Pharmaceuticals+0.21%-4.28%-28.06%-18.26%-88.76%FWPForward Pharma A/S0.00%0.00%0.00%0.00%0.00%MNPRMonopar Therapeutics+1.08%+1.08%-7.46%+77.57%-40.81%ONCSOncoSec Medical0.00%0.00%0.00%0.00%-70.60%Mysterious Gold Leverage Just Announced (Ad)World's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.Find out what it is and see how you can get in with just a few dollars.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADXSAyala PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AASLNASLAN Pharmaceuticals2.9064 of 5 stars3.55.00.00.03.00.80.6FWPForward Pharma A/SN/AN/AN/AN/AN/AN/AN/AN/AMNPRMonopar Therapeutics2.4146 of 5 stars3.55.00.00.00.61.70.6ONCSOncoSec MedicalN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADXSAyala Pharmaceuticals2.00HoldN/AN/AASLNASLAN Pharmaceuticals3.00Buy$11.332,396.33% UpsideFWPForward Pharma A/SN/AN/AN/AN/AMNPRMonopar Therapeutics3.00Buy$2.00222.06% UpsideONCSOncoSec MedicalN/AN/AN/AN/ACurrent Analyst RatingsLatest ASLN, ONCS, MNPR, FWP, and ADXS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/23/2024ASLNASLAN PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.004/15/2024ASLNASLAN PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.004/11/2024MNPRMonopar TherapeuticsJonestradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$2.003/18/2024ASLNASLAN PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$17.00 ➝ $9.003/13/2024ASLNASLAN PharmaceuticalsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$15.00 ➝ $10.00(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADXSAyala Pharmaceuticals$10K591.25N/AN/A($2.27) per share-0.24ASLNASLAN Pharmaceuticals$12M0.62N/AN/A($0.81) per share-0.56FWPForward Pharma A/SN/AN/AN/AN/A$10.09 per shareN/AMNPRMonopar TherapeuticsN/AN/AN/AN/A$0.38 per shareN/AONCSOncoSec MedicalN/AN/AN/AN/A$3.42 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADXSAyala Pharmaceuticals-$48.07M-$7.98N/A∞N/AN/A-3,967.23%-339.10%5/21/2024 (Estimated)ASLNASLAN Pharmaceuticals-$44.22M-$2.74N/AN/AN/AN/A-8,454.87%-95.72%4/26/2024 (Estimated)FWPForward Pharma A/S-$1.89MN/A0.00∞N/AN/AN/AN/AN/AMNPRMonopar Therapeutics-$8.40M-$0.61N/AN/AN/AN/A-115.79%-88.05%5/9/2024 (Estimated)ONCSOncoSec Medical-$34.18M-$15.29N/AN/AN/AN/A-868.29%-160.61%N/ALatest ASLN, ONCS, MNPR, FWP, and ADXS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/26/2024N/AASLNASLAN PharmaceuticalsN/A-$0.61-$0.61N/AN/AN/A4/12/2024Q4 2023ASLNASLAN PharmaceuticalsN/A-$0.78-$0.78-$0.78N/AN/A3/28/2024Q4 2023MNPRMonopar Therapeutics-$0.17-$0.12+$0.05-$0.12N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADXSAyala PharmaceuticalsN/AN/AN/AN/AN/AASLNASLAN PharmaceuticalsN/AN/AN/AN/AN/AFWPForward Pharma A/SN/AN/AN/AN/AN/AMNPRMonopar TherapeuticsN/AN/AN/AN/AN/AONCSOncoSec MedicalN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADXSAyala PharmaceuticalsN/A0.300.30ASLNASLAN PharmaceuticalsN/A1.841.84FWPForward Pharma A/SN/A18.43N/AMNPRMonopar TherapeuticsN/A4.174.17ONCSOncoSec MedicalN/A0.890.89OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADXSAyala Pharmaceuticals7.18%ASLNASLAN Pharmaceuticals58.82%FWPForward Pharma A/S12.57%MNPRMonopar Therapeutics1.83%ONCSOncoSec Medical8.69%Insider OwnershipCompanyInsider OwnershipADXSAyala Pharmaceuticals0.63%ASLNASLAN Pharmaceuticals4.69%FWPForward Pharma A/S71.47%MNPRMonopar Therapeutics41.60%ONCSOncoSec Medical1.32%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableADXSAyala PharmaceuticalsN/A10.75 million10.68 millionNot OptionableASLNASLAN Pharmaceuticals3516.35 million15.58 millionOptionableFWPForward Pharma A/S47.09 million2.02 millionNot OptionableMNPRMonopar Therapeutics1117.45 million10.19 millionNot OptionableONCSOncoSec Medical404.55 million4.49 millionNot OptionableASLN, ONCS, MNPR, FWP, and ADXS HeadlinesSourceHeadlineIs OncoSec Medical Inc (ONCSQ) Stock a Good Investment?aaii.com - June 29 at 2:37 AMONCS - OncoSec Medical Incorporatedfinance.yahoo.com - June 24 at 8:41 AM0 analysts rank ONCS stock as an Overweightknoxdaily.com - June 23 at 6:54 PMWhy Is OncoSec Medical (ONCS) Stock Up 100% Today?markets.businessinsider.com - June 23 at 8:53 AMWhy John Wiley & Sons Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Sessionmsn.com - June 15 at 2:49 PMWhy Is OncoSec Medical (ONCS) Stock Down 48% Today?msn.com - June 15 at 9:48 AMOncoSec Announces Closing of $1.33 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rulesfinance.yahoo.com - May 18 at 8:59 PMOncoSec Medical plunges 35% lower on sale of 1.4M shares of common stockmsn.com - May 16 at 4:15 PMOncoSec Announces $1.33 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rulesfinance.yahoo.com - May 16 at 4:15 PMOncoSec is encouraged after FDA meeting to discuss proposed neoadjuvant melanoma clinical programfinance.yahoo.com - May 16 at 9:56 AMOncoSec Receives $3.49 Million to Strengthen its Balance Sheet After Selling its Net Operating Loss Tax Benefits Through The New Jersey Economic Development Authority NOL Programfinance.yahoo.com - April 27 at 8:26 AMOncoSec Announces Closing of $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rulesfinance.yahoo.com - April 11 at 5:48 PMWhy OncoSec Medical Shares Are Soaring Todaymsn.com - April 10 at 4:15 PMOncoSec Announces $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rulesfinance.yahoo.com - April 10 at 4:15 PMOncoSec Medical Inc (ONCS) is lower by 6.15% Tuesday In Premarket Tradingbenzinga.com - April 6 at 7:57 PMOncoSec Shares Disappointing Results From Skin Cancer Combo Therapy Trial, Sets Stage For Neoadjuvant Setting Studyfinance.yahoo.com - April 3 at 3:57 PMOncoSec crashes ~60% after TAVO-EP, Keytruda combo fails phase 2 skin cancer trialmsn.com - April 3 at 10:57 AMOncoSec Announces Clinical Data of the KEYNOTE-695 Trial Assessing TAVO™-EP in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Melanoma Refractory to anti-PD-1 Treatmentfinance.yahoo.com - April 3 at 10:57 AMOncoSec Medical Withdraws Planned Offering, Shares Rise Over 50%marketwatch.com - March 1 at 8:56 AMWhy is OncoSec Medical (ONCS) Stock Up 91% Today?msn.com - March 1 at 8:56 AMONCS.OQ - | Stock Price & Latest News | Reutersreuters.com - January 16 at 7:08 PMOncoSec Medical Stock (NASDAQ:ONCS), Quotes and News Summarybenzinga.com - January 5 at 3:51 PMPeering Into OncoSec Medical's Recent Short Interestmsn.com - December 8 at 5:34 PMOncoSec to Present at the RHK Capital Disruptive Growth Conference on December 6, 2022finance.yahoo.com - December 5 at 1:28 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAyala PharmaceuticalsNASDAQ:ADXSAyala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.ASLAN PharmaceuticalsNASDAQ:ASLNASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal antibody that targets the IL-13 receptor a1 subunit which is being developed for the treatment of atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune diseases. It has a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.Forward Pharma A/SNASDAQ:FWPForward Pharma A/S does not have significant operations. Previously, it operated as a biopharmaceutical company that focused on developing FP187 proprietary formulation of dimethyl fumarate for the treatment of inflammatory and neurological indications. Forward Pharma A/S was incorporated in 2005 and is headquartered in Copenhagen, Denmark.Monopar TherapeuticsNASDAQ:MNPRMonopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.OncoSec MedicalNASDAQ:ONCSOncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company's product pipeline includes KEYNOTE-695, which is in Phase 2 trial for the treatment of advanced melanoma; TAVO + SARS-CoV-2 spike glycoprotein, which is in Phase 1 clinical trial for the treatment of COVID-19; and TAVO + epacadostat + pembrolizumab, which is in Phase 1 clinical trial for the treatment of squamous cell carcinoma head and neck cancer. Its pipeline also comprises TAVO +nivolumab, which is in Phase 2 clinical trial for the treatment of breast cancer; TAVO + CXCL9 for the treatment of solid tumors; and OMS-100 and OMS-102, which are in Phase 2 clinical trial for the treatment of metastatic melanoma. OncoSec Medical Incorporated has clinical trial collaborations with Merck & Co., Inc. and its subsidiary in connection with the KEYNOTE-695 and KEYNOTE-890; and a research collaboration with Duke University's Center for Applied Therapeutics to evaluate TAVO in combination or sequenced with a HER2-plasmid vaccine. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. OncoSec Medical Incorporated was incorporated in 2008 and is headquartered in Pennington, New Jersey. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.